Inhibrx Biosciences (INBX) Operating Margin (2023 - 2025)
Historic Operating Margin for Inhibrx Biosciences (INBX) over the last 3 years, with Q2 2025 value amounting to 2106.85%.
- Inhibrx Biosciences' Operating Margin rose 1587911500.0% to 2106.85% in Q2 2025 from the same period last year, while for Sep 2025 it was 11949.57%, marking a year-over-year increase of 61676900.0%. This contributed to the annual value of 165724.0% for FY2024, which is 1535450600.0% down from last year.
- According to the latest figures from Q2 2025, Inhibrx Biosciences' Operating Margin is 2106.85%, which was up 1587911500.0% from 1595.43% recorded in Q1 2025.
- Inhibrx Biosciences' 5-year Operating Margin high stood at 1595.43% for Q1 2025, and its period low was 160898.0% during Q2 2024.
- Its 3-year average for Operating Margin is 49017.42%, with a median of 21956.66% in 2023.
- In the last 5 years, Inhibrx Biosciences' Operating Margin tumbled by -445247600bps in 2024 and then surged by 1587911500bps in 2025.
- Quarter analysis of 3 years shows Inhibrx Biosciences' Operating Margin stood at 5403.24% in 2023, then tumbled by -824bps to 49928.0% in 2024, then surged by 96bps to 2106.85% in 2025.
- Its Operating Margin stands at 2106.85% for Q2 2025, versus 1595.43% for Q1 2025 and 49928.0% for Q4 2024.